Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Secretome From Human Micro-Fragmented Adipose Tissue Affects In Vitro Monocytes/Macrophages Inflammatory Activity by ICAM-1 Expression.

Coccè V., Martegani E., Paino F., Doneda L., Alessandri G., Manfredi B.

Laboratory Study on Chronic Inflammation, published in Mediators Inflamm (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Mediators Inflamm (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41834645
DOI
10.1155/mi/9475320

Abstract (original English)

Micro-fragmented adipose tissue (MFAT) is regarded as one of the simplest and most practical biological preparations for clinical applications in tissue regenerative medicine. The clinical effectiveness of MFAT is attributed to its content of cells and growth factors that facilitate tissue regeneration. In this study, we investigated the biological activity of the secretome derived from cultured MFAT. Our primary focus was on its ability to influence the production of two inflammatory cytokines, RANTES (Regulated and Normal T Cell Expressed and Secreted) and MCP-1 (Monocyte Chemoattractant Protein-1), using ELISA assays, as well as its impact on the expression of Cell Adhesion Molecules (CAMs) on U-937 macrophages via flow cytometry. We also explored the potential of the MFAT secretome to affect the proliferation of both normal and cancer cells. Our results showed that the MFAT secretome inhibited the production of MCP-1 and RANTES, significantly reduced the expression of ICAM-1 (Intercellular Adhesion Molecule 1) on U-937 macrophages, and had no impact on the proliferation of normal or cancer cells. These findings suggest that the MFAT secretome is relatively safe and exhibits anti-inflammatory properties, supporting the idea that its clinical effectiveness in treating joint inflammation may, in part, be due to its paracrine effects.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansAdipose TissueMacrophagesIntercellular Adhesion Molecule-1Chemokine CCL2Chemokine CCL5MonocytesSecretomeInflammationCell Proliferation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research